Wake Forest Baptist Comprehensive Cancer Center

Running trials

• Recruiting

  A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)

  NCT07614022· Phase 1· Source

• Not yet recruiting

  Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy

  NCT07911540· Source

• Recruiting

  Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology

  NCT06897137· Source

• Recruiting

  Comprehensive Care for AYA: Needs Assessment Survey

  NCT07196241· Source

• Recruiting

  Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

  NCT07291297· Phase 2· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Source

• Recruiting

  LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Sarcoma Patients

  NCT06958107· Source

• Recruiting

  The Better, Harder, Faster, Stronger Study

  NCT07220512· Source

• Recruiting

  A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

  NCT06697600· Source

• Recruiting

  ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

  NCT06945042· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Source

• Recruiting

  Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

  NCT06580106· Source

• Recruiting

  Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study

  NCT06567704· Source

• Recruiting

  Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery

  NCT06607406· Source

• Recruiting

  Evaluation of the Pathobiology of CALR-mutated MPN Cells

  NCT06480591· Source

• Recruiting

  Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

  NCT05442216· Phase 2· Source

• Recruiting

  Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

  NCT05692635· Phase 2· Source

• Recruiting

  Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

  NCT05696782· Phase 2· Source

• Recruiting

  Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

  NCT05776524· Phase 2· Source

• Recruiting

  SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  NCT05303519· Phase 3· Source

• Active, not recruiting

  Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

  NCT05561374· Phase 1· Source

• Active, not recruiting

  Improving Exercise Capacity With a Tailored Physical Activity Intervention

  NCT05595577· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  NCT05503797· Phase 2· Source

• Active, not recruiting

  Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

  NCT05415358· Source

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Source

• Active, not recruiting

  Cardiac Outcomes With Near-Complete Estrogen Deprivation

  NCT05309655· Source

• Recruiting

  Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  NCT05281471· Phase 3· Source

• Recruiting

  Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma

  NCT05376592· Source

• Recruiting

  Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

  NCT04822337· Phase 1/2· Source

• Recruiting

  Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

  NCT04337580· Phase 2· Source

• Recruiting

  Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  NCT04253964· Phase 2· Source

• Recruiting

  Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

  NCT04375384· Phase 2· Source

• Active, not recruiting

  A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

  NCT04396821· Phase 1/2· Source

• Active, not recruiting

  Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  NCT04174742· Source

• Active, not recruiting

  Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

  NCT03257033· Phase 3· Source

• Recruiting

  I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  NCT01042379· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukemia5 recruiting
• Lung cancer5 recruiting
• Childhood cancers4 recruiting
• Multiple myeloma3 recruiting
• Ovarian cancer3 recruiting
• Sarcoma3 recruiting
• Head and neck cancer2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Bladder cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Glioblastoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Thyroid cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Assessing and Addressing Follow-up Care Needs That Will Facilitate Care Transitions for Cancer Survivors

  NCT06654245· Source

• Completed

  M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis

  NCT06441266· Source

• Completed

  COPD Care Pathway Among Patients With Cancer

  NCT05984680· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Source

• Completed

  Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors

  NCT06340503· Source

• Completed

  Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors

  NCT05796518· Source

• Terminated

  Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

  NCT05877404· Source

• Terminated

  Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

  NCT05597878· Phase 2/3· Source

• Completed

  Carotid Ultrasound to Identify Head and Neck Cancer Survivors With High Cardiovascular Risk After Radiation Therapy

  NCT05490875· Source

• Completed

  MOST EMPOWER: Optimizing An Emotion Regulation Intervention

  NCT04317417· Source

• Completed

  Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy

  NCT04415944· Phase 2· Source

• Withdrawn

  CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

  NCT03929211· Phase 1/2· Source

• Completed

  Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

  NCT04454489· Phase 2· Source

• Terminated

  Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

  NCT04327700· Phase 2· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· Source

• Terminated

  Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities

  NCT04037527· Phase 1· Source

• Completed

  Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

  NCT04388475· Phase 2· Source

• Completed

  Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

  NCT04134884· Phase 1· Source

• Completed

  Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy

  NCT03958747· Source

• Terminated

  Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

  NCT03926624· Phase 3· Source

• Completed

  Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

  NCT03702725· Phase 1· Source

• Completed

  Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

  NCT03867175· Phase 3· Source

• Terminated

  Medical Data Collection in the Formation of Precision Oncology Registry

  NCT03874065· Source

Trial sites

• Atrium Health Wake Forest Baptist - Comprehensive Cancer Center1 trial
• Atrium Health Wake Forest Baptist Comprehensive Cancer Center21 trials
• Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AH-WFBCCC)1 trial
• Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology1 trial
• Wake Forest Baptist Comprehensive Cancer Center38 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Myeloproliferative neoplasms8 works · 1 trials